Your shopping cart is currently empty

LEO 39652, a dual-soft PDE4 inhibitor, demonstrates potent inhibition of PDE4 subtypes A, B, C, and D with respective IC50 values of 1.2 nM, 1.2 nM, 3.0 nM, and 3.8 nM. Additionally, it inhibits TNF-α with an IC50 of 6.0 nM, indicating its potential for topical Atopic dermatitis (AD) research [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks | 6-8 weeks |
| Description | LEO 39652, a dual-soft PDE4 inhibitor, demonstrates potent inhibition of PDE4 subtypes A, B, C, and D with respective IC50 values of 1.2 nM, 1.2 nM, 3.0 nM, and 3.8 nM. Additionally, it inhibits TNF-α with an IC50 of 6.0 nM, indicating its potential for topical Atopic dermatitis (AD) research [1]. |
| Targets&IC50 | PDE4C2:3.0 nM (IC50), PDE4B:1.2 nM (IC50), TNF-α:6.0 nM (IC50), PDE4D:3.8 nM (IC50), PDE4A:1.2 nM (IC50) |
| In vitro | LEO 39652 exhibits significant unbound in vitro efficacy, as demonstrated by its capacity to inhibit LPS-induced TNF-α release in human peripheral blood mononuclear cells (PBMC) cultured in serum-free medium. Additionally, LEO 39652 demonstrates relatively high affinity for binding to human serum albumin[2]. |
| In vivo | LEO 39652 is inactivated both in blood and liver (dual-soft) while remaining stable in the skin[1]. Pharmacokinetic analysis reveals that LEO 39652 exhibits total clearance (rats 930, minipigs 200, and monkey 300 mL/min/kg) and ratio to total AUC (rats 4, minipigs 6, and monkey 6%) following intravenous administration (rats 0.075, minipigs 0.5, and monkeys 2.0 mg/kg)[1]. |
| Molecular Weight | 421.45 |
| Formula | C23H23N3O5 |
| Cas No. | 1445656-91-6 |
| Smiles | COc1ccc(-c2ccc3C(=O)OCc3c2)n2nc(nc12)C1(CC1)C(=O)OCC(C)C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (59.32 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.